[Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) Pub Date : 2025-03-30 DOI:10.29262/ram.v72i1.1424

Diego Gutiérrez-Fernández, Mónica Saldaña-Valderas, Marianela Iriarte-Gahete, Raquel De la Varga-Martínez, Rafael Pamies-Espinosa, Jose Carlos Roldán-Morales, Zahira Maria Franzón-Laz, Joan Doménech-W

{"title":"[Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab].","authors":"Diego Gutiérrez-Fernández, Mónica Saldaña-Valderas, Marianela Iriarte-Gahete, Raquel De la Varga-Martínez, Rafael Pamies-Espinosa, Jose Carlos Roldán-Morales, Zahira Maria Franzón-Laz, Joan Doménech-W","doi":"10.29262/ram.v72i1.1424","DOIUrl":null,"url":null,"abstract":"Background: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more unusual.Case report: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.Conclusion: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"72 1","pages":"76-79"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v72i1.1424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more unusual.

Case report: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.

Conclusion: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.

查看原文本刊更多论文

[因伊谢珠单抗引起全身反应的患者成功皮下脱敏]。

背景：Ixekizumab是一种高亲和力IgG4单克隆人源化抗体，可用于治疗强直性脊柱炎。良性皮肤反应是ixekizumab常见的不良反应，但全身性过敏反应更为罕见。病例报告：我们描述了一例54岁的女性HLAB27+脊柱炎患者。处方用ixekizumab 80mg皮下治疗（含聚山梨酸酯）。患者立即出现严重呼吸困难、皮肤红斑和潮红。皮内试验（0.8 mg/ml）在即时读数中明显呈阳性。患者计划根据8步方案接受ixekizumab脱敏治疗，具有良好的耐受性。结论：我们报告了一名HLAB27阳性脊柱炎患者接受ixekizumab治疗后出现全身ige介导反应。描述了一种成功且易于执行的皮下脱敏方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)

自引率

0.00%

发文量